Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing direct oral small molecule inhibitors of STAT3 (Signal Transducer and Activator of Transcription 3) to treat inflammatory, fibrotic, and proliferative diseases with significant unmet medical need. The company's pipeline includes two candidates: TTI-101, a first-generation STAT3 inhibitor in clinical development for hepatocellular carcinoma and idiopathic pulmonary fibrosis, and TTI-109, a phosphate prodrug designed to enhance drug delivery while maintaining the same mechanism. The company generates no revenue currently and plans to commercialize approved products independently in the United States and through strategic partnerships in other regions, retaining exclusive worldwide rights to its candidates and backed by a robust patent portfolio extending through the mid-2040s.